Neuronal vulnerability in Parkinson's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 50, 1997, Pages 79-88

  Hirsch, Etienne C ^a   Faucheux, B ^a   Damier, P ^a   Mouatt Prigent, A ^a   Agid, Y ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CELL LEVEL; CASE REPORT; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; CELL DEATH; METABOLISM; NERVE CELL; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SUBSTANTIA NIGRA;

CALCIUM; CALPAIN; DOPAMINE; LACTOFERRIN;

CALCIUM; CALPAIN; CELL DEATH; DOPAMINE; HUMANS; LACTOFERRIN; NERVE DEGENERATION; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0030614644     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6842-4_9     Document Type: Review

References (36)

1. Bogerts B, Häntsch J, Herzer M (1983) A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. Biol Psych 18: 951-969
2. Ceballos I, Lafon M, Javoy-Agid F, Hirsch E, Nicole A, Sinet PM, Agid Y (1990) Superoxide dismutase and Parkinson's disease. Lancet 335 i: 1035-1036
3. Damier P, Hirsch E, Javoy-Agid F, Zhang P, Agid Y (1993) Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52: 1-6
4. Damier P, Hirsch EC, Agid Y, Graybiel AM (1995) Pattern of cell loss in the substantia nigra in Parkinson's disease. Soc Neurosci Abstr 21: 1250
5. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389
6. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52: 1830-1836
7. Dexter DT, Carayon A, Vidailhet M, Ruberg M, Agid F, Agid Y, Lees AJ, Wells FR, Jenner P, Marsden CD (1990) Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 55: 16-20
8. Earle KM (1968) Studies in Parkinson's disease including X-ray fluorescent spectroscopy of formalin fixed tissue. J Neuropathol Exp Neurol 27: 1-14
9. Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32: 796-798
10. 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J Neurochem 60: 2238-2241
11. 125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys. Brain Res 691: 115-124
12. Faucheux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, Pierce A, Leveugle B, Kubis N, Hauw JJ, Agid Y, Hirsch EC (1995) Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson's disease. Proc Natl Acad Sci USA 92: 9303-9307
13. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114: 2283-2301
14. Hassler R (1937) Zur Normalanatomie der Substantia Nigra, Versuch einer architektonischen Gliederung. J Psychol Neurol 48: 1-55
15. Hassler R (1938) Zur Pathologies der Paralysis Agitans und des post enzephalitischen Parkinsonismus. J Psychol Neurol 48: 387-476
16. Hirsch EC, Graybiel AM, Agid Y (1988) Melanized dopaminergic neurons are differentially affected in Parkinson's disease. Nature 334: 345-348
17. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an x-ray microanalysis. J Neurochem 56: 446-451
18. 28K-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution and distribution in Parkinson's disease. Neurodegeneration 1: 83-93
19. Ito H, Goto S, Sakamoto S, Hirano A (1992) Calbindin-D28K in the basal ganglia of patients with Parkinsonism. Ann Neurol 32: 543-550
20. Iwamoto N, Thangnipon W, Crawford C, Emson PC (1991) Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease. Brain Res 561: 177-180
21. Jellinger K, Paulus W, Grundke-Iqbal I (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm 2: 327-340
22. Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MB (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 59: 1168-1171
23. Lee KS, Frank S, Vanderklish P, Arai A, Lynch G (1991) Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc Natl Acad Sci USA 88: 7233-7237
24. Leveugle B, Faucheux BA, Bouras C, Nillesse N, Spik G, Hirsch EC, Agid Y, Hof PR (1996) Immunohistochemical analysis of the iron binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol 91: 566-572
25. 28k is located in the midbrain dopaminergic neurons which are resistant to MPTP-induced degeneration. Soc Neurosci Abstr 17: 1275
26. Mouatt-Prigent A, Agid Y, Hirsch EC (1994) Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? Brain Res 668: 62-70
27. Mouatt-Prigent A, Karlsson JO, Agid Y, Hirsch EC (1996) Increased m-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in cell death? Neuroscience 73: 979-987
28. Nilsson E, Alafuzoff I, Blennow K, Blomgren K, Hall C M, Janson I, Karlsson I, Wallin A, Gottfries CG, Karlsson JO (1990) Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue. Neurobiol Aging 11: 425-431
29. Nixon RA, Quackenbush R, Vitto A (1986) Multiple calcium-activated neutral proteinases (CANP) in mouse retinal ganglion cell neurons: specificities for endogenous neuronal substrates and comparison to purified brain CANP. J Neurosci 6: 1252-1263
30. Ostwald K, Hagberg H, Andine P, Karlsson JO (1993) Up-regulation of calpain activity in neonatal rat brain after hypoxic-ischemia. Brain Res 630: 289-294
31. Rami A, Krieglstein J (1993) Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res 609: 67-70
32. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520
33. Siman R, Gall C, Perlmuter LS, Christian C, Baudry M, Lynch G (1985) Distribution of calpain I, an enzyme associated with degenerative activity, in rat brain. Brain Res 347: 399-403
34. Yamada T, McGeer PL, Baimbridge KG, McGeer P (1990) Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin D28k. Brain Res 26: 303-307
35. Yoshida KI, Sorimachi Y, Fujiwara M, Hironaka K (1995) Calpain is implicated in rat myocardial injury after ischemia or reperfusion. Jpn Circ J 59: 40-48
36. Zhang P, Anglade P, Hirsch EC, Javoy-Agid F, Agid Y (1994) Distribution of manganese dependent superoxide dismutase in the human brain. Neuroscience 61: 317-330